CagriSema / working resource
Primary source desk
Keep the original documents and the limits of their conclusions within reach.
Start with the product-specific question
Cagrilintide and semaglutide
Combination-trial intelligence with transparent current status. What should I know about cagrilintide and semaglutide: what each component does?
Open the CagriSema library ↗REDEFINE1 randomized 3417 adults with overweight/obesity without diabetes to combination, either component, or placebo, all with lifestyle support, for 68 weeks.
Read the original record ↗
The original record comes first.
These are starting points for the CagriSema library. Read the source's exact question, product, population and date. A source can be authoritative for one claim and irrelevant to another.
Keep claims and sources together.
REDEFINE1 randomized 3417 adults with overweight/obesity without diabetes to combination, either component, or placebo, all with lifestyle support, for 68 weeks.
Supporting record ↗In REDEFINE1, mean weight change using the treatment-policy estimand was−20.4% with the combination versus−3.0% with placebo; estimated difference−17.3 percentage points.
Supporting record ↗Gastrointestinal adverse events occurred in 79.6% of combination recipients versus 39.9% of placebo recipients in REDEFINE1.
Supporting record ↗REDEFINE2 randomized 1206 adults with type 2 diabetes and BMI≥27; mean week 68 weight change was−13.7% versus−3.4% with placebo.
Supporting record ↗These fields stay in this page until you leave or reload. No notes are saved or transmitted. Print a copy if you want to keep your work. Educational organization tools do not replace clinical advice.